D-dimer thresholds rule out PE in meta-analysis
Data from a large review support use of D-dimer levels to diagnose PE without imaging.
Anticoagulant choice in antiphospholipid syndrome–associated thrombosis
Are direct oral anticoagulants (DOACs) as efficacious and safe as vitamin K antagonists (VKAs) in treating thrombosis secondary to...
Apixaban a reasonable alternative to warfarin in patients with severe renal impairment
Is apixaban a safe alternative to warfarin in patients with severe renal impairment?
Apixaban outmatches rivaroxaban for VTE in study
These real-world findings may guide selection of initial anticoagulant therapy, according to authors of the paper.
Apixaban noninferior to low-molecular-weight heparin in cancer-associated VTE
Is oral apixaban as safe and effective as subcutaneous dalteparin in treating venous thromboembolism (VTE) in patients with underlying cancer?
Ticagrelor reversal agent achieves quick hemostasis: REVERSE-IT
The monoclonal antibody bentracimab, which can rapidly reverse ticagrelor, was found effective and safe in an FDA-requested interim analysis of a...
D-dimer unreliable for ruling out pulmonary embolism in COVID-19
Autopsy findings reveal venous thromboembolism in patients with COVID-19
What pathologic features contribute to the cause of death in COVID-19?
Rivaroxaban’s single daily dose may lead to higher bleeding risk than other DOACs
Corroborating previous studies, Iceland researchers report that rivaroxaban poses the highest risk of GI bleeding, compared with other DOACs.
CVST after COVID-19 vaccine: New data confirm high mortality rate
“This is the biggest series, and as an international series, it gives a broader perspective from a larger range of countries.”